Atjaunināt sīkdatņu piekrišanu

Clinical Handbook of Psychotropic Drugs 2017 22nd Revised edition [Spiral bound]

4.23/5 (22 ratings by Goodreads)
Edited by , Edited by , Edited by
  • Formāts: Spiral bound, 432 pages, height x width: 279x216 mm
  • Izdošanas datums: 25-May-2017
  • Izdevniecība: Hogrefe Publishing
  • ISBN-10: 0889374961
  • ISBN-13: 9780889374966
Citas grāmatas par šo tēmu:
  • Spiral bound
  • Cena: 114,42 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
Clinical Handbook of Psychotropic Drugs 2017 22nd Revised editionPalielināt
  • Formāts: Spiral bound, 432 pages, height x width: 279x216 mm
  • Izdošanas datums: 25-May-2017
  • Izdevniecība: Hogrefe Publishing
  • ISBN-10: 0889374961
  • ISBN-13: 9780889374966
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780889374966.html
Keywords:
New in this edition:* Third-generation antipsychotics with major additions and changes * Pharmacogenomics fully revised * ECT thoroughly revised and updated* BLT / rTMS with extended references* Extrapyramidal side effects chart extended* Antidepressants vilazodone and vortioxetine with extended coverage * New chart of agents under investigation for treatment of substance use disorders* Approved and off-label indications updated* New unapproved treatments with significant updates, including anti-inflammatories, hormones, and 5-HT3 antagonists, in depres-sion, dementia, schizophrenia, and anxiety disorders* New agents include: TGAs N-arylpiperazine (brexiprazole, Rexulti) and phenylpiperazine: (cariprazine, Vrylar), hypnotic suvorexant (Belsomra)* New formulations and trade names include: Brisdelle (paroxetine mesylate), Irenka (duloxetine capsules), Invega Trinza, Dyanavel XR, Evekeo, Zenzedi, Adzenys XR-ODT, Aptensio XR, Quillichew ER / Quil-livant XRThe Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.* Independent, unbiased* Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options* Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing impli-cations, and much more - all you need to know for each class of drug* Potential interactions and side effects summarized in comparison charts* With instantly recognizable icons and in full color throughout, allow-ing you to find at a glance all the information you seek * Clearly written patient information sheets available for download as printable PDF files This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs

Recenzijas

With the increasing rate of prescriptions of psychotropic drugs, this book should be on the desk of every physician. This new edition of a widely acclaimed handbook conveys, with exceptional clarity and immediacy, meaningful information that would be difficult to find elsewhere. Such information is crucial for understanding the side effects and vulnerabilities induced by psychotropic drug treatment.;Psychotherapy and Psychosomatics 2017;86:320-321; "A user-friendly and practical resource guide to using psychotropic drugs in any setting... The handbook is well organized and covers almost every treatment used in psychiatry, arranged by disease state and class. Each medicine or class of medicine is subjected to a thorough review ofnearly everything one should understand. It is easy to read and/or reference quick information. The comprehensive information on each class of drugs is what makes this book so useful. As a psychiatrist who routinely prescribes medications, I find this handbook invaluable."; Corey Goldstein, MD, Rush University Medical Center, in Doody's Listings and Reviews, 2016; The Clinical Handbook of Psychotropic Drugs is a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. The handbook is continually updated and provides current evidence-based and clinically relevant information to optimize patient care. The contents are independent and unbiased, with easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions, etc.) providing a quick overview of treatment options."; Barry G. Woodcock, in International Journal of Clinical Pharmacology & Therapeutics, vol. 55, 2017

Antidepressants
2(84)
Selective Serotonin Reuptake Inhibitors (SSRI)
3(13)
Norepinephrine Dopamine Reuptake Inhibitor (NDRI)
16(6)
Serotonin Norepinephrine Reuptake Inhibitors (SNRI)
22(7)
Serotonin-2 Antagonists/Reuptake Inhibitors (SARI)
29(6)
Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI)
35(4)
Serotonin Modulator and Stimulator (SMS)
39(4)
Noradrenergic/Specific Serotonergic Antidepressants (NaSSA)
43(4)
Nonselective Cyclic Antidepressants
47(9)
Monoamine Oxidase Inhibitors
56(1)
Reversible Inhibitor of MAO-A (RIMA)
56(4)
Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs)
60(6)
Irreversible MAO-B Inhibitor
66(4)
Effects of Antidepressants on Neurotransmitters/Receptors
70(1)
Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors
71(1)
Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses
72(3)
Antidepressant Doses and Pharmacokinetics
75(3)
Switching Antidepressants
78(2)
Antidepressant Augmentation Strategies
80(6)
Electroconvulsive Therapy (ECT)
86(7)
Bright Light Therapy (BLT)
93(4)
Repetitive Transcranial Magnetic Stimulation (rTMS)
97(5)
Antipsychotics
102(91)
"Second-Generation" Antipsychotics/SCAs
108(29)
"Third-Generation" Antipsychotics/TGAs
137(12)
"First-Generation" Antipsychotics/FGAs
149(17)
Effects of Antipsychotics on Neurotransmitters/Receptors
166(1)
Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes
167(1)
Relative Tolerability Profiles of Antipsychotics
168(2)
Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses
170(2)
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections)
172(10)
Comparison of Long-Acting IM Antipsychotics
182(5)
Switching Antipsychotics
187(1)
Antipsychotic Augmentation Strategies
188(5)
Antipsychotic-Induced Extrapyramidal Side Effects and Their Management
193(17)
Extrapyramidal Adverse Effects of Antipsychotics
193(5)
Treatment Options for Extrapyramidal Side Effects
198(5)
Effects on Extrapyramidal Symptoms
203(1)
Comparison of Agents for Treating Acute Extrapyramidal Side Effects
204(2)
Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects
206(4)
Anxiolytic (Antianxiety) Agents
210(16)
Benzodiazepines
211(7)
Comparison of the Benzodiazepines
218(4)
Buspirone
222(4)
Hypnotics/Sedatives
226(15)
L-Tryptophan
232(2)
Comparison of Hypnotics/Sedatives
234(7)
Mood Stabilizers
241(33)
Lithium
241(9)
Anticonvulsants
250(15)
Comparison of Anticonvulsants
265(7)
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses
272(2)
Drugs for ADHD
274(22)
Psychostimulants
274(9)
Atomoxetine
283(3)
Comparison of Drugs for ADHD
286(4)
α2 agonists
290(3)
Augmentation Strategies in ADHD
293(3)
Drugs for Treatment of Dementia
296(13)
Cholinesterase Inhibitors
296(5)
Memantine
301(4)
Comparison of Drugs for Treatment of Dementia
305(4)
Sex-Drive Depressants
309(6)
Comparison of Sex-Drive Depressants
311(4)
Drugs of Abuse
315(31)
Alcohol
317(4)
Stimulants
321(5)
Hallucinogens
326(7)
Opioids
333(4)
Inhalants/Aerosols
337(2)
Gamma-hydroxybutyrate (GHB)/Sodium Oxybate
339(2)
Flunitrazepam (Rohypnol)
341(1)
Nicotine/Tobacco
342(4)
Treatment of Substance Use Disorders
346(24)
Acamprosate
347(2)
Disulfiram
349(3)
Naltrexone
352(3)
Buprenorphine
355(4)
Methadone
359(5)
Pharmacotherapy for Nicotine/Tobacco Use Disorder
364(1)
Comparison of Treatments for Nicotine/Tobacco Use Disorder
365(5)
Unapproved Treatments of Psychiatric Disorders
370(17)
Adrenergic Agents
371(2)
Anti-inflammatory Agents
373(2)
Dopaminergic Agents
375(2)
CABA Agents/Anticonvulsants
377(2)
Hormones
379(2)
NMDA Agents
381(3)
5-HT3 Antagonists
384(1)
Miscellaneous
384(3)
Natural Health Products
387(12)
Ginkgo Biloba
387(2)
Kava Kava
389(1)
Melatonin
390(1)
Omega-3 Polyunsaturated Fatty Acids
391(3)
S-Adenosyl-L-Methionine (SAMe)
394(1)
St. John's Wort
395(1)
Valerian
396(1)
Vitamins
397(2)
Pharmacogenomic Information for Common Psychotropic Drugs
399(11)
Genotypes Affecting Pharmacokinetic Properties of Psychotropic Drugs
400(1)
Pharmacogenomics-Based Dose Adjustment Recommendations and Guidelines
401(7)
Genotype Effects on Pharmacokinetic Properties of Psychotropic Drugs
408(2)
Glossary 410(4)
Drug Use in Pregnancy and Effects on Breast Milk 414(1)
Patient Information Sheets 415(3)
Appendix: Neuroscience-Based Nomenclature (NbN) 418(4)
Index of Drugs 422
Ric M. Procyshyn; BSc (Pharm), MSc, PharmD, PhD; Department ofPsychiatry, University of British Columbia, Vancouver, BC, Canada;British Columbia Mental Health & Addictions Research Institute,Vancouver, BC, Canada.Kalyna Z. Bezchlibnyk-Butler; BScPhm, FCSHP; Toronto, ON, Canada.J. Joel Jeffries; MB, FRCPC, DFCPA; Centre for Addiction and MentalHealth and Department of Psychiatry, University of Toronto,Toronto, ON, Canada.